1. Home
  2. BCAB vs OFAL Comparison

BCAB vs OFAL Comparison

Compare BCAB & OFAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • OFAL
  • Stock Information
  • Founded
  • BCAB 2007
  • OFAL 2013
  • Country
  • BCAB United States
  • OFAL United States
  • Employees
  • BCAB N/A
  • OFAL N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • OFAL Military/Government/Technical
  • Sector
  • BCAB Health Care
  • OFAL Consumer Discretionary
  • Exchange
  • BCAB Nasdaq
  • OFAL Nasdaq
  • Market Cap
  • BCAB 21.6M
  • OFAL 21.4M
  • IPO Year
  • BCAB 2020
  • OFAL 2025
  • Fundamental
  • Price
  • BCAB $0.45
  • OFAL $1.52
  • Analyst Decision
  • BCAB Hold
  • OFAL
  • Analyst Count
  • BCAB 3
  • OFAL 0
  • Target Price
  • BCAB $1.00
  • OFAL N/A
  • AVG Volume (30 Days)
  • BCAB 561.4K
  • OFAL 389.6K
  • Earning Date
  • BCAB 08-07-2025
  • OFAL 01-01-0001
  • Dividend Yield
  • BCAB N/A
  • OFAL N/A
  • EPS Growth
  • BCAB N/A
  • OFAL N/A
  • EPS
  • BCAB N/A
  • OFAL N/A
  • Revenue
  • BCAB $11,000,000.00
  • OFAL $202,007.00
  • Revenue This Year
  • BCAB N/A
  • OFAL N/A
  • Revenue Next Year
  • BCAB N/A
  • OFAL N/A
  • P/E Ratio
  • BCAB N/A
  • OFAL N/A
  • Revenue Growth
  • BCAB N/A
  • OFAL N/A
  • 52 Week Low
  • BCAB $0.24
  • OFAL $1.09
  • 52 Week High
  • BCAB $2.53
  • OFAL $9.79
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 65.33
  • OFAL N/A
  • Support Level
  • BCAB $0.35
  • OFAL N/A
  • Resistance Level
  • BCAB $0.38
  • OFAL N/A
  • Average True Range (ATR)
  • BCAB 0.03
  • OFAL 0.00
  • MACD
  • BCAB 0.01
  • OFAL 0.00
  • Stochastic Oscillator
  • BCAB 90.66
  • OFAL 0.00

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About OFAL OFA Group Ordinary Shares

OFA Group, through its subsidiary, provides architectural services, including design and fit-out services for commercial and residential buildings in Hong Kong. The design service includes both the consultation with staff and the actual design work and the company provides a specific conceptualized design with layout plans, detailed design drawings, advice relating to, among other things, budgetary consideration, optimal use of space, the materials, fittings, furniture, appliances and other items to be used to produce a preliminary design plan and quotation. Its works include installing protective materials to cover floors or walls, installing or constructing partition walls, windows, window frames, and decorative fittings, furniture or fixtures, installing plumbing systems, etc.

Share on Social Networks: